Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo

Proteasome-addicted neoplastic malignancies present a considerable refractory and relapsed phenotype with patients exhibiting drug resistance and high mortality rates. To counter this global problem, novel proteasome-based therapies are being developed. In the current study, we extensively character...

Descripción completa

Detalles Bibliográficos
Autores principales: Tandon, Vasudha, Vala, Ruturajsinh M., Chen, Albert, Sah, Robert L., Patel, Hitendra M., Pirrung, Michael C., Banerjee, Sourav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837819/
https://www.ncbi.nlm.nih.gov/pubmed/35088066
http://dx.doi.org/10.1042/BSR20212721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837819/
https://www.ncbi.nlm.nih.gov/pubmed/35088066
http://dx.doi.org/10.1042/BSR20212721

Ejemplares similares